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Vitamin C and Disease: Insights from the Evolutionary Perspective
Abstract
The role of vitamin C at the physiological and cellular levels is indisputable. In line with this, blood level of
vitamin C is inversely related to disease parameters such as risk of cancer, cardiovascular disease and mortality
in prospective cohort and correlational studies. At the same time, adequately powered clinical intervention
studies consistently provide no evidence for a beneficial effect of supplementing vitamin C. Here we provide a
framework to resolve this apparent conflict. Besides providing an overview of the widely-known facts
regarding vitamin C, we review evidence that are of potential relevance but are seldomly mentioned in the
context of vitamin C. We invoke the glucose-ascorbate antagonism (GAA) theory which predicts that as a
consequence of their molecular similarity glucose hinders the entry of vitamin C into cells. Integrating data
coming from research at the cellular level, those from clinical, anthropological and dietary studies, in the
present hypothesis paper we propose an evolutionary framework which may synthesize currently available
data in the relation of vitamin C and disease. We put forward that instead of taking vitamin C as a supplement,
an evolutionary adapted human diet based on meat, fat and offal would provide enough vitamin C to cover
physiological needs and to ward off diseases associated with vitamin C deficiency.
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1. Introduction 
Vitamin C is one of the most widely taken nutritional supplements [1,2]. Health professionals 
as well as laymen attribute a number of health benefits to vitamin C such as boosting the 
immune system or preventing the common cold and cancer. Whilst the role of vitamin C in 
physiologic processes is well-established, there is little or no high-grade evidence supporting 
that taking vitamin C as a supplement is indeed beneficial. We will summarize existing 
research data with a special emphasis on aspects that are seldomly mentioned in the context of 
vitamin C. As such, we invoke the glucose-ascorbate antagonism (GAA) theory, which 
proposes that availability of vitamin C for cells is determined by glucose concentration [3]. 
We review evidence from cellular physiology as well as dietary studies carried out in Inuit 
people to support the GAA theory and the view that the source of vitamin C as well as 
composition of diet is crucial for optimal vitamin C supply. In this review we propose a 
concept which may be suitable for synthesizing data coming from diverse sources and/or that 
are apparently conflicting. The frames of the hypothesis are formed by a major, albeit often 
neglected principal: evolution. We put forward that apparent controversies regarding vitamin 
C can be readily resolved by an evolutionary approach. 
 
2. Biosynthesis and biological significance of vitamin C 
In most mammals vitamin C is produced from glucose in the liver. Species that are unable to 
synthesize this nutrient rely on dietary uptake from its food sources [4]. Vitamin C, in synergy 
with vitamin E, is known to have a role in reducing lipid peroxidation [5]. Vitamin C also acts 
as a co-factor in at least eight enzymatic reactions including those involved in the synthesis of 
collagen and carnitine [6]. 
Vitamin C exists in two redox states: ascorbic acid (AA), and its oxidized form, 
dehydroascorbic acid (DHAA). Most actions of vitamin C can be attributed to AA which acts 
as a reducing agent donating electrons to various reactions [7]. The oxidised form of vitamin 
C is then recycled back to AA. Both AA and DHAA are absorbed in the small intestine [7]. 
Absorption is almost complete at doses <200 mg but the degree of absorption decreases as 
intake increases [8]. Uptake of AA from the intestine relies on an active transport mechanism 
of sodium dependent vitamin C transporters (SVCT) while uptake of DHAA relies on 
facilitative diffusion by facilitative glucose transporters (GLUT) [9]. Within the enterocytes, 
absorbed DHAA is converted to AA thereby producing low intracellular DHAA 
concentration which by a gradient facilitates further DHAA uptake. DHAA may be taken up 
from the blood by several cell types that reduce it to AA. DHAA can be filtered from the 
plasma by renal corpuscules and then reabsorbed in the renal tubules for subsequent reduction 
[10]. Some organs accumulate vitamin C (AA) 10-50-fold higher than the blood level of it. 
These include tissues of high metabolic activity such as adrenal glands, thymus, eye lens, 
retina, brain, pancreas, kidney, lymph nodes and lymphocytes [11]. 
AA cannot penetrate the blood brain barrier thus vitamin C is taken up in its oxidised 
form DHAA which is then reduced back to AA for retaining it within brain cells [12]. A 
similar transport mechanism exists for vitamin C entering the mitochondria [9]. AA is 
accumulated within the mitochondria where it has a role to scavange free radicals abundantly 
produced by mitochondrial function [13]. Several pathological conditions have been shown to 
be associated with impaired redox cycling of vitamin C. For example, conditions associated 
with inflammation such as diabetes, trauma, surgery, sepsis and wound healing are also 
known to be characterized by decreased AA concentrations along with elevated DHAA 
concentrations in both plasma and leucocytes [10]. This is believed to be due to increased 
level of oxidants such as hydroxyl radicals, peroxyl radicals and superoxide anion requiring 
more AA than could be regenerated from DHAA [10].  
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3. Shortage and overdose of vitamin C 
Shortage of vitamin C causes scurvy, presenting with symptoms including malaise, gum 
disease, poor wound healing, shortness of breeth and bone pain. Scurvy occurred frequenty 
among salesmen in mediaeval times. In current western societies it may occur in subjects with 
alcoholism where it typically presents along with deficiencies of other vitamins [14]. Oral 
megadose (>1000 mg) of vitamin C may cause diarrhea, nausea, abdominal bloating and 
heatburn [4]. There is evidence that vitamin C supplementation increases the risk of forming 
kidney stones [4]. Megadoses of vitamin C may lead to the development of vitamin B12 
deficiency [4], a phenomenon explained by redox reactions of AA converting vitamin B12 
into a biologically inactive analogue [6]. As an additional side effect, in glucose-6-phosphate 
dehydrogenase deficiency AA has been shown to have a hemolytic effect [6]. Intrevenous 
megadose of vitamin C may result in diarrhea, nausea, headache, decreased appetite and 
fatigue [16].  
 
4. Evolutionary perspective 
Vitamin C is an essential nutrient for humans who are unable to synthesize and thus have to 
obtain it from its dietary sources. Loss of the ability to synthesize vitamin C is not unique 
among mammals: e.g. guinea pigs, monkeys and apes also lack this ability. Non-synthesizing 
species, including humans, lack the L-gulonolactone oxidase (GULO) enzyme which is 
required in the last enzymatic step of synthesis of vitamin C from glucose [4]. In the genome 
of humans and that of the anthropoid primates a non-functional gene is present instead of the 
GULO gene. Loss of the ability to synthesize vitamin C in primates is believed to have 
occurred about 60 million years ago at the time of the split of the two primate suborders: 
Strepsirrhini and Haplorhini [17]. Strepsirrhine primates including lemurs, lorises, and 
galagos are able to produce vitamin C while haplorhine primates such as tarsiers, monkeys 
and apes obtain it from dietary sources. 
In the medical literature losing the ability to synthesize vitamin C in the course of 
evolution is usually interpreted as an imperfection leaving our health vulnerable. However 
with an evolutionary attitude such an ”imperfection” is inconceivable given that species that 
are currently living represent the highest level of adaptation to their environment. Non-human 
species lacking the GULO gene are not regarded imperfect either. It would be hard to believe 
that the Homo genus would have been so successful in terms of survival and spatial spread 
with a deteriorating genetic mutation. We assume that in the ancestral environment, where our 
hominoid predecessors lived for 2.6 million years, loss of internal synthesis of vitamin C was 
not disadvantegous. As one possible explanation, Ames et al. [18] proposed that during the 
primate evolution uric acid might have taken over the antioxidant function of vitamin C, a 
hypothesis based on the striking paralellism between the inability to break down uric acid and 
the loss of the ability of vitamin C synthesis in primates [19]. 
 
5. Dietary sources of vitamin C 
Recommended Dietary Allowances (RDA) of vitamin C, as suggested by the Institute of 
Medicine, is 90 mg for males and 75 for females. According to the NHANES survey between 
2003 and 2004, 7% was vitamin C deficient (serum concentration <11.4 μmol/L) in an US 
population where 37% of men and 47% of women was taking vitamin C supplements [20].  
 The estimated average requirement (EAR) is set at 75 mg/d on the basis that it will 
lead to 80% saturation of neutrophil AA concentrations without substantial urinary excretion, 
thereby maximizing antioxidant effects. The RDA is derived from the EAR by assuming a 
coefficient of variation (CV) of 10% in nutritional needs and adding twice the CV to the EAR 
to yield an RDA that presumably covers the needs of 97-98% of the population [21]. Failure 
or inconclusiveness of intervention studies with vitamin C may be due to the fact that vitamin 
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C in these studies was given to people who had already been meeting or nearly meeting their 
requirement as defined by the RDA.  
Current dietary recommendations concentrate on plant sources of vitamin C. The 
WHO, for example, recommend a minimum of 400g of fruit and vegetable per day also in an 
attempt to ensure other micronutrients [22]. The belief that plant sources are ideal for vitamin 
C supply roots back to James Lind who in 1747 discovered that scurvy, a devasting disease of 
English sailors, can be prevented and reversed by fresh fruits. In fact, several lines of 
evidence indicate that people may remain free of scurvy on diets lacking fruits and vegetables. 
In hunter-gatherer societies organ meats and especially liver, marrow and brain are 
highly favoured. These latter organs, as also described above, accumulate high level of 
vitamin C [23,24] and are rich in other vitamins too [25]. At odds with dietary 
recommendations in the western world, the majority of hunter gatherer societies are subsisting 
on meat based diets yet remain free of scurvy [26,27,28]. In the study of Cordain et al. [26] 
168 of the 229 hunter gatherer societies subsisted on diets containing at least 55% hunted 
and/or fished food. In fact the ratio of animal food may be even higher given that hunther 
gatherers also eat insects, invertebrates and other small animals that are collected by gathering 
[26]. If both plant and animal foods are available, hunther gatherers clearly prefer the latter 
[26,27].    
Traditionally living arctic people represent extreme examples of animal food relience. 
Among the Inuit scurvy was not observed until the 20th century [23]. Studies show that the 
traditional diets of northern populations, including the Inuit diet, provide enough amount of 
vitamin C. Fediuk [23], for example, reported an average intake of 38 mg of vitamin C/day 
from meat and organs. However, on special occasions such as after successful whale hunts 
intake may reach 340 mg/day [23]. Animal parts with highest vitamin C content include 
”muktuk”, epidermis of the beluga whale (containing 36 mg/100 mg of vitamin C) and the 
liver (containing 24 mg/100 mg of vitamin C) as well as the brain (containing 15 mg/100 mg 
of vitamin C) of land and sea mammals [23,24]. In the 1970th, in the study of Geraci and 
Smith [29] daily intake of vitamin C in a hunting Inuit community was in the range 10-120 
mg, much higher than found earlier in a national survey of Canada assessing Inuit populations 
in larger settlements with transitional cultures [29]. Westernalization of native societies 
brought substantial changes in life style along with a decline in the access to traditional foods. 
In parallel, an increasing portion of the Inuit people became at risk for scurvy [23].  
Several examples show that not only native people may subsist on meat-fat based 
diets. It is known that arctic travellers of European descent living on canned Western type 
food were frequently affected by scurvy but this was not the case in those who had access to 
traditional foods [25]. The arctic explorer Vilhjalmur Steffanson, for example, lived on the 
Inuit diet for nine years and remained completely healthy. In 1930 an experiment was set up 
in which Steffanson along with a fellow explorer lived on an exclusive meat diet for one year 
[30]. No sign of vitamin deficiency, including scurvy, was noticed despite of the absence of 
vitamin supplementation. Voegtlin, first proponent of the human evolutionary diet, put 
forward that the diet humans are evolutionary adapted to is based on animal fat, meat and 
offal, and is of full nutritional value. Along with this, he argued against the usefulness of 
supplementing vitamin C [25]. We would like to emphasize that those hunter gatherers 
subsisting on diets containing larger amounts of fruits and vegetables, may also have access to 
enough vitamin C. This may be due to the combined sources of animal and plant vitamin C 
along with a carbohydrate intake being still much lower than on an average Western type diet. 
Anyhow, the Kitavan islanders for example, who are known to consume much carbohydrate 
as compared with other indigenous people, exhibit low blood glucose levels (on average 3.5 
mmol/l in the young population) [31].   
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The authors of the present paper are rehabilitating patients with chronic diseases by 
using a diet we refer to as the paleolithic ketogenic diet [32-36]. This is an animal fat-meat 
based diet which is close to the diet originally proposed by Voegtlin [25]. The paleolithic 
ketogenic diet excludes foods that were not available for preagricultural humans such as 
cereal grains, milk and dairy, vegetable oils, nightshades, legumes, refined sugars and foods 
with additives. It also excludes foods that may be included in the popular versions of the 
paleolithic diet such as oilseeds, coconut, coconut oil, artificial sweeteners, vitamin as well as 
other supplements. The paleolithic ketogenic diet also differs from the popular paleolithic diet 
in that it restricts vegetables and fruits to an amount of <30% (by weight) and thus ensures 
ketosis. The suggested fat:protein macronutrient ration is 2:1 (in grams). We encourage red 
and fat meats and the regular intake of organ meats. Like other proponents of the paleolithic 
diet [25,26] we advise patients against taking vitamin C supplements. Our clinical experience, 
also shown by the example of our published cases [32-36], indicate that neither scurvy nor 
other nutritional deficiency emerge in the absence of vitamin C supplementation while 
adhering to the paleolithic ketogenic diet. As an important distinction, this is not the case with 
the classical form of the ketogenic diet where scurvy may occur [37] likely due to limited 
intake of both animal and plant sources of vitamin C. 
Another potential benefit of animal derived vitamin C pertains to cooking. It is widely 
known that vitamin C content of foods degrade at higher temperatures. However, cooking-
related loss of vitamin C seems to be smaller in animal-derived foods as compared with plant-
derived ones as assessed both by the analysis of the Inuit diet [29,23] and by comparison of 
food items in publicly available food databases. For example, according to the USDA's 
National Nutrient Database for Standard Reference in the raw spinach there is 28.1 mg/100 g 
of vitamin C while cooked spinach contains only 9.8 mg/100 g of it. At the same time, raw 
and cooked forms of pork liver contain comparable amounts of vitamin C: while the former 
contains 25.3 mg/100 g the latter contains 23.6 mg/100 g of vitamin C. 
  
6. Vitamin C and disease 
In the following we review data from those clinical studies representing the highest grade 
evidence available and have a hard clinical endpoint. In such an attempt we have searched 
pubmed and google scholar databases for studies that include terms ”vitamin C” or ”ascorbic 
acid” in combination with ”mortality”, "cancer”, ”cardiovascular disease”, ”stroke”, 
”hypertension” and ”common cold”. We also searched for ”intravenous vitamin C therapy”. 
We then reviewed search results for each of the above condition to select those studies that (1) 
include the most subjects/patients, (2) have a sound methodology and (3) and assess a hard 
endpoint/clinically meaningful variable. Parameters which were regarded as hard clinical 
endpoint include: bivariate variables (such as death or the occurrence of specific events 
including stroke or cardiovascular events, and having a diagnosis of a specific disease), 
survival time, incidence of common cold, and blood pressure itself in hypertension. We 
disregarded studies that rely on soft clinical endpoints of disease e.g. cholesterol level in 
cardiovascular disease, the role of which in cardiovascular disease is debated. Prospective 
cohort and correlational studies are presented separately from intervention studies. For 
prospective and correlational studies we only included studies that assessed blood level of 
vitamin C and excluded those that rely on estimated dietary intake of vitamin C. Reasons for 
this include probable inadequacies in estimation of the vitamin C content of foods and the 
low/variable correlation between dietary intake and the blood level of vitamin C [38]. The 
low measured correlation between dietary and blood vitamin C in these studies is due to fact 
that blood vitamin C not only depend on intake but on other factors including differences in 
relative partitioning between plasma and intracellular concentration as well as differences in 
excretion and oxidation rates [6]. From our point of view it is of upmost importance that 
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dietary studies assessing vitamin C intake, either epidemiological or interventional studies, 
limited the estimation of vitamin C to the plant sources while neglecting the animal sources of 
it. The reason for selecting the conditions of common cold, cardiovascular disease and cancer 
in the present manuscript lies in the fact that large studies of vitamin C (either prospective or 
randomized controlled studies) are available for these conditions only. Out of the three 
conditions, cancer will be in the focus, given the predominance of studies assessing cancer. 
 
6.1. Prospective cohort and correlational studies: blood level of vitamin C and disease 
For an overview of prospective cohort and correlational studies of blood level of vitamin C 
and disease including mortality, cancer, cardiovascular disease, stroke and hypertension see 
Table 1. 
 
 
Table 1. 
Major prospective cohort and correlational studies of vitamin C and disease 
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* number of patients in the gastric cancer group 
Note that all studies indicate an inverse association between blood concentration of AA and 
mortality/morbidity. 
 
6.1.1. Mortality 
In the EPIC-Norfolk prospective population study, plasma concentration of AA was inversely 
related to mortality from all-causes as well as from cardiovascular disease and ischaemic heart 
disease. Mortality risk in the top quintile was half the risk in the lowest quintile [39]. A study 
based on an NHANES II. database found an inverse relation between dying from any cause 
and low AA in men but there was no association in women [40].  In one study with elderly, 
AA concentration was shown to be inversely associated with subsequent mortality in both 
males and females [41] while in another study AA concentration was inversely associated 
with mortality from stroke but not from coronary heart disease [42]. Male cardiovascular 
mortality in the Basel Prospective Study was also inversely associated with plasma level of 
vitamin C [43]. In hemodialysis patients, low level of vitamin C was shown to be a risk factor 
for cardiovascular morbidity and mortality which was explained by vitamin C ameliorating 
vascular dysfunction generally seen in patients with renal failure [44].  
 
5.1.2. Cancer 
In the EPIC-Norfolk study, vitamin C level was inversely related to cancer mortality in males 
but not in females [40]. In an NHANES II. study, cancer risk was inversely related to AA in 
males [45]. Unexpectedly, in females high level of AA was found to be associated with 
increased cancer risk [45]. A case control study showed increased risk for gastric cancer for 
those with low plasma level of vitamin C [46] but no association was found for dietary 
vitamin C intake [46]. In hospice patients low plasma concentrations were associated with 
shorter survival [47]. 
 
6.1.3. Cardiovascular disease 
In an NHANES II. study, serum AA was inversely related with the prevelance of coronary 
heart disease and stroke [48]. In several studies, including the Epic-Norfolk prospective 
population study, low plasma concentration of vitamin C was associated with increased stroke 
risk [49]. In cross-sectional studies, blood pressure in middle aged and elderly [50] as well as 
in young adults [51] was found to be inversely associated with blood AA.  
 
6.2. Intervention studies of vitamin C 
 
6.2.1. Oral supplementation of vitamin C 
For an overview of the oral vitamin C intervention studies related to mortality, common cold, 
cardiovascular disease and high blood pressure see Table 2. Given the high number of 
intervention studies with vitamin C available in the literature, in the present review we 
concentrate on RCTs and metaanalyses. 
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Table 2. 
Major metaanalyses and RCTs of oral vitamin C supplementation related to mortality, 
common cold, cardiovascular disease and hypertension. No study report a clinically 
meaningful benefit. 
CVD: cardiovascular disease; MD: missing data; SBP: systolic blood pressure 
 
6.2.1.1. Mortality 
A recent Cochrane review examining mortality as an endpoint found that supplementation of 
antioxidants including vitamin C have no effect on overall mortality [52].  
 
6.2.1.2. Common cold 
The latest Cochrane review [53] concluded that vitamin C supplementation has no effect on 
the incidence of common cold. However, a modest reduction of sympoms was consistently 
found in the reviewed studies [53].  
 
6.2.1.3. Cardiovascular disease 
The Women's Antioxidant Cardiovascular Study, a randomized controlled study (RCT), found 
no effect of vitamin C supplementation in the secondary prevention of cardiovascular disease 
[54]. Another RCT, the Physicians' Health Study II., did neither find vitamin C to be 
beneficial in the prevention of cardiovascular events [55]. In regards to high blood pressure, a 
metaanalysis of twenty-nine trials of blood pressure indicated a statistically significant yet 
clinically not meaningful decrease of 3.8 mmHg in systolic blood pressure [56].  
 
6.2.1.4. Cancer 
The idea that vitamin C may be beneficial in cancer treatment stems from Linus Pauling who 
argued that high doses of vitamin C (10 g/day) given intravenously may be useful in the 
treatment of cancer [57]. This assumption was based on a study of 100 patients with advanced 
cancer who as compared to historical controls survived three to four times longer [57]. The 
study was later criticized because of the absence of an appropriate control group. The study 
was repeated with improved methodology and the authors still reported survival benefit in the 
vitamin C group [58,59]. However, subsequent prospective controlled studies that were 
carried out at the Mayo clinic were unable to repeat results. These studies, however, used oral 
administration of vitamin C rather than intravenous administration [60,61]. Unlike the 
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original study [57], Creagan et al. [60] included patients who previously received 
chemotherapy while the study by Moertel et al. [61] included cancer patients with no prior 
chemotherapy. 
Prospective RCTs, like the Physicians’ Health Study II., did not find vitamin C 
supplementation to be effective in the prevention of total cancers, prostate and in other solid 
tumors [62]. No effect of vitamin C supplementation on cancer incidence and mortality was 
seen in another randomized trial, the Women's Antioxidant Cardiovascular Study [63]. A 
metaanalysis by Coulter et al. [64] also concluded that vitamin C provide no prevention of 
cancer.  
For an overview of the oral vitamin C intervention studies related to cancer see Table 
3. 
 
 
Table 3. 
Cancer-related intervention studies of oral vitamin C. 
a patients received IVC therapy for 10 days followed by oral vitamin C 
b besides oral vitamin C some patients received IVC therapy too 
c number of patients in the vitamin C group 
* Number of patients treated with vitamin C 
RCT: randomised controlled trial; NA: not applicable 
 
6.2.2. High dose intravenous vitamin C (IVC) therapy in cancer 
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Vitamin C is known to poorly absorb when administered orally at higher doses: immune cells 
saturate at 100 mg daily, and renal excretion of AA increases above this dose [8]. Therefore, it 
was claimed that blood concentrations of vitamin C in the Mayo Clinic studies [60,61] might 
not have reached a concentration producing the cytotoxic effect to tumor cells seen in in vitro 
studies [65]. With intravenous administration, the tightly regulated absorption and transport of 
vitamin C is bypassed and therefore result in a much (30- to 70-fold) higher than 
physiological blood level of vitamin C [66]. Cytotoxicity of AA to cancer cells was based on 
in vitro studies which suggested that AA in concentrations higher than physiological in the 
extracellular space act as a pro-oxidant and through the formation hydrogen peroxide kill 
cancer cells [67]. However, in a recent study the cytotoxic effect was abolished at 
physiological concentrations of iron which prevented the accumulation of hydrogen peroxide 
[68]. It was suggested that previous studies disregarding in vivo concentration of iron had 
significantly overestimated the anticancer effect of AA [68].   
Currently, no more than a single RCT is available that assessed the effect of IVC 
therapy in cancer patients [69]. This indicated a reduction of chemotherapy induced side 
effects in ovarian cancer patients but no significant effect in terms of survival was found [69]. 
In an uncontrolled study of metastatic pancreatic cancer patients, Monti et al. [70] reported 
minor decrease in the size of the tumor without evidence of prolonged survival. In another 
study, of the 16 patients with solid tumors no one experienced an objective tumor response 
[71]. In a study by Mikirova et al. [72], decreased level of inflammatory markers was seen 
following IVC therapy but no positive effect was reported on disease progression and 
survival. Clearly, no antitumor effect was evident in phase I. clinical trials studies including 
studies by Welsh et al. [73] and Hoffer et al. [74]. Two other clinical group studies by 
Riordan [75] and Yeom et al. [76] did neither provide evidence for an anticancer effect. A 
more recent phase I-II. clinical study by Hoffer et al. [77] reported transient (lasting for 3-13 
months) stable disease in 3 out of the 16 patients in the study. Actually all the existing group 
studies have failed to provide evidence for a benefit in hard clinical endpoints such as 
survival. At the same time, it is important to mention that except for the seminal study of 
Cameron and Pauling [57] all the above IVC studies included patients with prior or 
concurrent chemotherapy. Thus the possibility suggested by Creagan et al. [60] that cancer 
patients with no chemotherapy may benefit more from IVC therapy cannot be entirely 
excluded. 
Currently only case reports are available describing survival benefit following IVC 
therapy [78,17]. Overall, from the available group studies it only seems that high dose IVC 
therapy is relatively safe, reduces chemotherapy induced side effects but provide no benefit in 
terms of hard clinical endpoints including survival in cancer patients also receiving 
chemotherapy.   
For an overview of the IVC studies related to cancer see Table 4. 
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Table 4. 
IVC therapy studies in cancer. Except for a small RCT (Ma et al. 2014) all studies contain 
only a single group. Each study included patients with prior or concurrent chemotherapy. No 
study reported an apparent benefit in terms of survival. 
ICV: intravenous vitamin C; RCT: randomized controlled trial 
 
6.3. Summary of the prospective cohort and intervention studies of vitamin C 
Prospective cohort studies unequivocally found an inverse relation with the blood level of 
vitamin C for mortality, cancer and cardiovascular disease for each of the specific disease 
populations. Two prospective studies [40,45] when assessing males and females separately, 
reported the inverse association in males only. We assume that the absence of an inverse 
association in females may be due to differential habits of males and females in taking 
supplements. Although in the two studies it was not possible to retrieve data on supplement 
use, females are known to be more prone to take vitamin C supplements [20], and thus a 
higher serum level of AA in females may reflect the effect of supplementation which may not 
be preventive. Overall results from prospective studies are in sharp contrast with the 
intervention studies where none of the studies reported a clinically meaningful benefit as 
regards mortality, incidence of common cold, cardiovascular events, and prevention or 
treatment of cancer.     
 
7. The glucose-ascorbate antogonism theory 
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The glucose-ascorbate antagonism (GAA) theory was first proposed by John Ely as early as 
the 1970s [3]. The theory postulates that given the structural similarity between glucose and 
vitamin C, the two molecules compete for same transport system to enter cells [10]. It has 
been shown that cellular uptake of both AA and DHAA may be competitively antagonized by 
elevated glucose levels. Specifically, AA uptake by the small intestine enterocytes was shown 
to be inhibited by elevated glucose concentration [9]. DHAA transport into cells was shown 
to be impaired by high blood glucose concentration in most cell types including adipocytes, 
erythrocytes, granulosa cells, neutrophils, osteoblasts and smooth muscle cells [10]. 
A potential limitation of the GAA theory pertains to the lack of in vivo studies in 
animals and in humans. Diabetes, however, can be regarded as a natural model to study 
interaction between blood glucose and vitamin C in vivo in humans. Studies with diabetic 
patients are in line with the GAA therory. Two studies in type 2 diabetes [79,80] indicated 
that in spite of similar dietary intake of vitamin C, patients have decreased levels of plasma 
AA as compared to normal controls. Furthermore, serum level of AA inversely correlated 
with glucose levels [80] and in another study with glycated hemoglobin of diabetic patients 
[81]. Diabetes is also known to be associated with impaired renal reabsorption of AA [82] 
which likely contributes to the low level of AA in patients. 
Uptake of glucose and DHAA also share the feature of insulin-dependency on the 
GLUT4 glucose transporter primarily found in muscle and adipose tissue [83]. In type 1 
diabetes, deficiency of insulin has been shown to impair DHAA uptake of lymphoblasts [84]. 
Such a decreased DHAA uptake, through impaired AA accumulation, may lead to 
compromized immune system function in type 1 diabetes patients [84]. The effect of glucose 
seems to be immediate on intracellular AA given that intravenous glucose administration 
results in a prompt decrease in the AA concentration of leukocytes [85]. Also consistently 
with the GAA theory, blood level of vitamin C is inversely related with obesity [86] a 
correlate of increased carbohydrate intake.  
Controlling hyperglycemia has also been suggested as an adjunct to cancer therapy 
[87]. Hyperglycemia in cancer patients is known to be associated with reduced intracellular 
AA concentration. Such a decrease results in impaired actions of AA, including a decreased 
activity of the hexose monophosphate shunt, a patway important in optimal immune cell 
functioning [87]. In cardiovascular disease, the association of high blood glucose and low AA 
concentration is also consistent with the GAA mechanism, and may plausibly explain 
functional impairments such as lipid peroxidation and endothelial dysfunction which are 
known to contribute to the generation of atherosclerosis [87]. 
As an additional parallelism, the study by Johnstone et al. [88] compared the effect of 
two high protein diets: one with low (in fact ketogenic) and another with medium 
carbohydrate content. To the surprise of the investigators, higher concentration of blood 
vitamin C was found on the low carbohydrate diet. Yet, the difference was explained by other 
factors.  
AA is known to have a role in scavenging reactive oxygen species within the 
mitochondria. Reactive oxygen species within the mitochondria have been suggested to have 
a role in the development of degenerative disorders including cancer [89]. Given the fact that 
carbohydrate based Western type nutrition is associated with increased production of reactive 
oxygen species in the mitochondria [89], it is plausible to speculate that the need for AA 
would be decreased when on a low carbohydrate diet.  
In human brush border membrane vesicles evaluated ex vivo, AA uptake is 
competitively antagonized by glucose [9] coming abundantly from carbohydrate based diets 
may explain why according to a metaanalysis dietary intake and plasma level of AA were 
only moderately correlated [38]. Importantly, estimation of AA intake in this study relied on 
plant sources only. Negligation of animal sources of vitamin C is typical in the case of the 
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other dietary studies too. This fact together with the loose association between the intake 
estimate and blood level indicate that plants are not ideal sources of vitamin C. Additionally, 
flavonoids abundantly found in fruits and vegetables were also shown to inhibit vitamin C 
uptake by enterocytes [90]. We are not aware of studies assessing the relation between animal 
sources of vitamin C and blood level of it. The striking dissociation between epidemiological 
and intervention studies, as revealed in this review for mortality, cardiovascular disease and 
cancer, may be regarded as an indication that vitamin C taken as a supplement may not be an 
optimal way to obtain this nutrient.  
Chronic diseases such as obesity, diabetes, neurodegenerative diseases, cancer and 
cardiovascular diseases being associated by the cluster of carbohydrate overconsumption [91], 
mitochondrial dysfunction [92], increased production of reactive oxygen species [92] and 
decreased blood level of vitamin C also point to the GAA as a common mechanism beyond 
these pathologic conditions. It can be speculated that increased dietary intake of carbohydrates 
and resulting low level of blood AA are important factors contributing to the development of 
chronic degenerative disorders. 
As a further parallelism, the hypothesis proposed in the present paper also fits well 
with the Warburg theory postulating that cancer is originating from a metabolic dysfunction 
including insufficient mitochondrial oxidative phosphorylation and compensatorily enhanced 
glycolysis [93]. Cancer cells are highly dependent on glucose and are unable to use fat or 
ketones for energy [94], a metabolic failure ketogenic diets are aimed to exploit. We suggest 
that an animal based, low carbohydrate high fat diet (instead of the currently used ketogenic 
diets) may provide vitamin C not only in sufficient amounts but also in a bioavailable form, 
and thus may be more appropriate for the treatment of cancer as compared with the versions 
of the classical ketogenic diets that are currently used in clinical trials e.g. [95]. 
 
8. Conclusion 
From the prospective cohort and correlational studies it is clear that higher blood level of AA 
is associated with lower mortality and morbidity in several chronic conditions. At the same 
time, high-grade evidence from clinical intervention studies indicate that vitamin C taken as a 
supplement provide little or no benefit in the prevention or treatment of chronic diseases. 
Indeed, apart from intervention studies of common cold where minor benefit was reported, no 
single RCT is available that found a clinically meaningful benefit in hard clinical endpoints of 
chronic diseases including cancer and cardiovascular diseases. We put forward that the 
discrepancy between correlational and interventional studies, as regards the role of vitamin C, 
is only apparent and may be resolved by introducing the GAA theory. As detailed above, 
metabolism of vitamin C, including absorption and its uptake by several cell types, is 
inhibited by increasing glucose concentration. Western type diets resulting in carbohydrate 
overconsumption and high blood level of glucose may inhibit utilization of vitamin C also 
when taken as a supplement. Current dietary guidelines, instead of animal sources, 
concentrate on plant sources of vitamin C, thereby also increasing carbohydrate load and 
intake of polyphenols which both inhibit vitamin C utilization. By contrast, studies of 
contemporary hunter-gatherer societies as well as documentations of the arctic people from 
the 18th and 19th century indicate no signs of scurvy despite subsisting on diets predominated 
by foods of animal origin and using no vitamin supplements. Our own clinical experience 
with the paleolithic ketogenic diet also shows improving health parameters and long-term 
sustainability of meat-fat based diet in the absence of vitamin C supplementation. It may be 
anticipated that supplementing vitamin C while on a Western type diet may not reproduce the 
biochemical and physiological complexity of the evolutionary adapted way to utilize vitamin 
C. Even though the amount of dietary vitamin C consumed on an animal meat-fat based diet 
may be lower as compared to dietary intake from some fruits and vegetables, the former may 
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ensure a higher bioavailability of vitamin C. We believe that loss of vitamin C synthesis was 
not deleterious in the ancestral environment humans are evolutionary adapted to. Rather, a 
mismatch between our current diet and ancestral physiology may explain why deficient levels 
of vitamin C are associated with disease. Instead of supplementing vitamin C, changing our 
nutrition as a whole and adopting a meat-fat based diet, even if it may sound a radical 
solution, may be a better choice to support vitamin C homeostasis. Bearing in mind that 
”nothing in biology makes sense except in the light of evolution” [96] this concept is in 
accordance with the major organizing principle of the living world: evolution. 
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